The aim of this project is to learn more about the mechanism of neutralization of cross-reactive immune responses to the influenza virus surface glycoproteins, hemagglutinin and neuraminidase, and to investigate the quantitative contribution of these mechanisms to protection. To approach this we will map the epitopes of a large panel of human (in collaboration with Project 2) and mouse cross-reactive anti-neuraminidase antibodies in order to define broadly neutralizing epitopes. Further, efforts will be made to characterize the quantitative contribution of different mechanisms of neutralization of a vast panel of broadly reactive antistalk and anti-neuraminidase monoclonal antibodies (of human and mouse origin, in collaboration with Project 2) and polyclonal sera. This work will involve in vivo imaging as well as a panel of assays that measure inhibition of viral entry/fusion, viral egress, hemagglutinin maturation, neuraminidase inhibition, complement activation and others (Project 3 will focus on antibody-dependent cell-mediated cytotoxicity). Finally, we use recombinant chimeric hemagglutinin and neuraminidase expressing influenza B viruses to study the impact of polyclonal anti-stalk and anti-neuraminidase responses on influenza virus pathogenesis and transmission in the mouse, guinea pig and ferret model.

Public Health Relevance

Understanding mechanisms of broad neutralization of influenza viruses based on humoral responses against the influenza virus surface glycoproteins is essential for the establishment of new, more accurate correlates of protection and for the development of assays to measure them. It is important to investigate the potency and quantitative contribution of single mechanisms to protection in polyclonal sera as basis for rational vaccine design and information about broadly neutralizing epitopes on the influenza virus neuraminidase will greatly impact on the development of neuraminidase based vaccines. Addressing these points is crucial to set the stage for the development of broader and longer lasting influenza virus vaccines which would also enhance our pandemic preparedness against emerging viruses like H7N9.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI109946-01
Application #
8667694
Study Section
Special Emphasis Panel (ZAI1-ZL-I (J1))
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
1
Fiscal Year
2014
Total Cost
$302,360
Indirect Cost
$51,957
Name
Icahn School of Medicine at Mount Sinai
Department
Type
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Ho, Irvin Y; Bunker, Jeffrey J; Erickson, Steven A et al. (2016) Refined protocol for generating monoclonal antibodies from single human and murine B cells. J Immunol Methods 438:67-70
Chen, Chi-Jene; Ermler, Megan E; Tan, Gene S et al. (2016) Influenza A Viruses Expressing Intra- or Intergroup Chimeric Hemagglutinins. J Virol 90:3789-93
Krammer, Florian (2016) Novel universal influenza virus vaccine approaches. Curr Opin Virol 17:95-103
Nachbagauer, Raffael; Choi, Angela; Izikson, Ruvim et al. (2016) Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans. MBio 7:e01996-15
Tan, Gene S; Leon, Paul E; Albrecht, Randy A et al. (2016) Broadly-Reactive Neutralizing and Non-neutralizing Antibodies Directed against the H7 Influenza Virus Hemagglutinin Reveal Divergent Mechanisms of Protection. PLoS Pathog 12:e1005578
He, Wenqian; Tan, Gene S; Mullarkey, Caitlin E et al. (2016) Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus. Proc Natl Acad Sci U S A 113:11931-11936
Neu, Karlynn E; Henry Dunand, Carole J; Wilson, Patrick C (2016) Heads, stalks and everything else: how can antibodies eradicate influenza as a human disease? Curr Opin Immunol 42:48-55
DiLillo, David J; Palese, Peter; Wilson, Patrick C et al. (2016) Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J Clin Invest 126:605-10
Henry Dunand, Carole J; Leon, Paul E; Huang, Min et al. (2016) Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection. Cell Host Microbe 19:800-13
Hamilton, Jennifer R; Sachs, David; Lim, Jean K et al. (2016) Club cells surviving influenza A virus infection induce temporary nonspecific antiviral immunity. Proc Natl Acad Sci U S A 113:3861-6

Showing the most recent 10 out of 39 publications